Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target

Benzinga Newsdesk www.benzinga.com Negative 81.5%

Neg 81.5% Neu 0% Pos 0%

Citizens analyst Silvan Turkcan reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and maintains $11 price target.